ProPhase Labs, Inc.
PRPH- Exchange
- OTC
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0000868278
No open-market purchases or sales by ProPhase Labs, Inc. insiders were filed in the last 90 days; 2 institutions reported holding it in 13F filings for Q2 2026, worth $2 in total; no superinvestor holds it.
13F holders, Q3 2021
Institutional positions in ProPhase Labs, Inc. as of Sep 30, 2021. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 21
- −2 vs. Q2 2021
- Shares held
- 1.65M
- +42.4K (+2.6%) vs. Q2 2021
- Total value
- $8.56M
- −$1.39M (−13.9%) vs. Q2 2021
- New holders
- 4
- 9 more added
- Sold out
- 6
- 6 more reduced
Compare with Q2 2021: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting PRPH on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 2 | $2 |
| Q1 2026 | 2 | $2 |
| Q4 2025 | 17 | $92.9K |
| Q3 2025 | 29 | $1.36M |
| Q2 2025 | 33 | $1.05M |
| Q1 2025 | 37 | $2.02M |
| Q4 2024 | 30 | $1.91M |
| Q3 2024 | 27 | $4.23M |
| Q2 2024 | 29 | $7.27M |
| Q1 2024 | 32 | $11.0M |
| Q4 2023 | 27 | $7.63M |
| Q3 2023 | 35 | $8.56M |
| Q2 2023 | 45 | $15.8M |
| Q1 2023 | 39 | $18.6M |
| Q4 2022 | 51 | $26.7M |
| Q3 2022 | 43 | $30.3M |
| Q2 2022 | 39 | $24.9M |
| Q1 2022 | 22 | $10.8M |
| Q4 2021 | 25 | $10.8M |
| Q3 2021 | 21 | $8.56M |
| Q2 2021 | 23 | $9.95M |
| Q1 2021 | 29 | $9.58M |
Institutions, Q3 2021
Shares, value and share of portfolio for each institution holding ProPhase Labs, Inc.; share changes are against Q2 2021.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Captrust Financial Advisors | 1,000 | $5.00K | 0.00% | 00.0% | Unchanged |
| Wells Fargo & Company | 1,606 | $8.00K | 0.00% | −4−0.2% | Reduced |
| JPMorgan Chase & Co | 5,730 | $30.0K | 0.00% | +5,730 | New |
| Morgan Stanley | 10,314 | $54.0K | 0.00% | +1,485+16.8% | Added |
| Northern Trust Corp | 18,866 | $98.0K | 0.00% | −984−5.0% | Reduced |
| Commonwealth Equity Services, LLC | 18,866 | $98.0K | 0.00% | 00.0% | Unchanged |
| HighVista Strategies LLC | 20,256 | $105.0K | 0.07% | +20,256 | New |
| Citadel Advisors LLC | 21,759 | $113.0K | 0.00% | +5,896+37.2% | Added |
| Marshall Wace, LLP | 22,801 | $119.0K | 0.00% | +22,801 | New |
| State Street Corp | 27,195 | $141.0K | 0.00% | +13,400+97.1% | Added |
| Bank of America Corp | 28,644 | $149.0K | 0.00% | +44+0.2% | Added |
| BlackRock Inc. | 28,778 | $150.0K | 0.00% | +3,647+14.5% | Added |
| Susquehanna International Group, LLP | 31,487 | $164.0K | 0.00% | −37,795−54.6% | Reduced |
| Bank of New York Mellon Corp | 49,000 | $254.0K | 0.00% | −42,090−46.2% | Reduced |
| Kamunting Street Capital Management, L.P. | 98,888 | $514.0K | 0.28% | −24,305−19.7% | Reduced |
| Avidian Wealth Solutions, LLC | 105,202 | $547.0K | 0.04% | +50,239+91.4% | Added |
| Geode Capital Management, LLC | 105,857 | $550.0K | 0.00% | +3,152+3.1% | Added |
| Bank of Montreal | 158,587 | $821.0K | 0.00% | +158,587 | New |
| Perritt Capital Management Inc | 188,400 | $980.0K | 0.54% | +10,500+5.9% | Added |
| Renaissance Technologies LLC | 236,510 | $1.23M | 0.00% | −50,810−17.7% | Reduced |
| Vanguard Group Inc | 467,342 | $2.43M | 0.00% | +1,004+0.2% | Added |
| Millennium Management LLC | 0 | $0 | 0.00% | −46,575−100.0% | Sold out |
| Acadian Asset Management LLC | 0 | $0 | 0.00% | −21,123−100.0% | Sold out |
| Dimensional Fund Advisors LP | 0 | $0 | 0.00% | −19,530−100.0% | Sold out |
| UBS Group AG | 0 | $0 | 0.00% | −9,040−100.0% | Sold out |
| Tower Research Capital LLC (TRC) | 0 | $0 | 0.00% | −1,471−100.0% | Sold out |
| Advisory Services Network, LLC | 0 | $0 | 0.00% | −600−100.0% | Sold out |